Table 2 Summary of findings for SBP and PP on dulaglutide treatment effect in participants with T2D
| Â | Â | Weight-dependent effect (mmHg) | Weight-independent effect (mmHg) | Total effect (mmHg) | % Weight-independent (%) |
|---|---|---|---|---|---|
Mediation meta-analysis of placebo-controlled trials (AWARD-1, 5, 8, 10, 11, and Ferdinand et al.) | |||||
 Dula 1.5 mg vs. PBO | SBP | − 0.9 (− 1.4, − 0.5) | − 1.5 (− 2.6, − 0.3) | − 2.6 (− 3.8, − 1.5) | 64 |
PP | − 0.4 (− 0.6, − 0.1) | − 2.0 (− 3.0, − 1.0) | − 2.5 (− 3.5, − 1.5) | 86 | |
Mediation analysis for dose response (AWARD-11) | |||||
 Dula 4.5 mg vs. Dula 1.5 mg | SBP | − 0.7 (− 1.1, − 0.4) | − 0.3 (− 1.6, 1.0) | − 1.0 (− 2.2, 0.3) | 29 |
PP | − 0.4 (− 0.6, − 0.2) | − 0.9 (− 1.8, 0.2) | − 1.2 (− 2.2, − 0.1) | 70 | |
Indirect comparison of Dula 4.5Â mg vs. PBO (AWARD-5 and 11) | |||||
 Dula 4.5 mg vs. PBO | SBP | − 2.0 (− 2.9, − 1.1) | − 1.5 (− 4.2, 1.2) | − 3.5 (− 6.2, − 0.8) | 43 |
PP | − 1.1 (− 1.7, − 0.5) | − 1.8 (− 4.0, 0.4) | − 2.9 (− 5.1, − 0.7) | 62 | |